Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

In an interview with Arthur Stril, chief business officer and interim CFO at Cellectis, we explore how gene editing and ...

The clinical trial results of India’s first CAR T-cell therapy, published in The Lancet, show that it worked for nearly 73 ...

Cancer metastasis, the spread of cancer to organs, is a major cause of cancer-related deaths. Once cancer spreads to multiple ...

A first-of-a-kind therapy that inhibits a population of T cells proved active and safe in a phase 3 trial for moderate to severe atopic dermatitis, introducing a novel mechanism to treat ...

Chimeric antigen receptor T-cell therapy improves not only lupus disease activity but also other related conditions that ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

X-linked severe combined immunodeficiency disease (X-SCID) is a rare genetic disorder characterized by profound defects in ...

A study on the long-term safety of CAR T-cell therapy for B-cell lymphoma patients reveals a favourable safety profile with ...

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...